First 3-in-1 inhaler combining indacaterol glycopyrronium and mometasone furoate, launched in the UK for treatment of asthma

Enerzair Breezhaler is licensed for maintenance treatment of asthma in adults who are not adequately treated by combination of a long-acting ß2 agonist and high-dose inhaled corticosteroid, and who have had 1 or more asthma exacerbations in the previous year.

Monthly Index of Medical Specialities